Compare
Aardvark Therapeutics, Inc. vs TherapeuticsMD, Inc. vs Nature's Sunshine Products Inc vs Lisata Therapeutics, Inc.
| Latest fiscal year | Aardvark Therapeutics, Inc. AARD | TherapeuticsMD, Inc. TXMD | Nature's Sunshine Products Inc NATR | Lisata Therapeutics, Inc. LSTA |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $0 | $3.02M | $480.14M | $170.0K |
| Revenue growth (YoY) | n/a | +71.6% | +5.7% | -83.0% |
| Gross margin | n/a | n/a | 72.4% | n/a |
| Operating margin | n/a | -145.3% | 5.2% | n/m |
| Net margin | n/a | -18.8% | 4.3% | n/m |
| Net income | -$57.59M | -$569.0K | $20.45M | -$16.59M |
| EPS (Diluted) | -$2.93 | -$0.05 | $1.06 | -$1.91 |
| Operating cash flow | -$54.17M | $2.45M | $35.32M | -$15.95M |
| Free cash flow | -$54.27M | n/a | $28.84M | -$15.98M |
| Cash & equivalents | $47.05M | n/a | $93.89M | $15.96M |
| Total assets | $117.18M | $37.66M | $261.15M | $17.74M |
| Total liabilities | $10.55M | $10.78M | $99.59M | $3.14M |
| Shareholders' equity | $106.63M | $26.88M | $161.55M | $14.86M |
| Return on year-end equity | -54.0% | -2.1% | 12.7% | -111.7% |
| Shares outstanding | 21.82M | 11.57M | 17.51M | 8.83M |
Revenue, most recent five fiscal years
| Fiscal year | Aardvark Therapeutics, Inc. | TherapeuticsMD, Inc. | Nature's Sunshine Products Inc | Lisata Therapeutics, Inc. |
|---|---|---|---|---|
| Latest | $0 Ended 2025-12-31 | $3.02M Ended 2025-12-31 | $480.14M Ended 2025-12-31 | $170.0K Ended 2025-12-31 |
| 1 year earlier | n/a | $1.76M Ended 2024-12-31 | $454.36M Ended 2024-12-31 | $1.00M Ended 2024-12-31 |
| 2 years earlier | n/a | $1.30M Ended 2023-12-31 | $445.32M Ended 2023-12-31 | $0 Ended 2023-12-31 |
| 3 years earlier | n/a | $69.96M Ended 2022-12-31 | $421.91M Ended 2022-12-31 | $0 Ended 2022-12-31 |
| 4 years earlier | n/a | $2.57M Ended 2021-12-31 | $444.08M Ended 2021-12-31 | n/a |